Evoke Pharma Inc reports results for the quarter ended in December - Earnings Summary

Evoke Pharma

14/03/2024 21:02

* Evoke Pharma Inc  EVOK.OQ  reported a quarterly adjusted
loss
of 59 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -53 cents.  The lone analyst forecast for the quarter was
for a loss of 50 cents per share. 
    * Revenue rose 110.6% to $1.68 million from a year ago;
analysts
expected $1.63 million. 
    * Evoke Pharma Inc's reported EPS for the quarter was a loss
of 59
cents​.
    * The company reported a quarterly loss of $1.99 million.
    * Evoke Pharma Inc shares had fallen by 39.0% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Evoke
Pharma Inc
is $7.00 

This summary was machine generated from LSEG data March 14 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.50          -0.59          Missed
 Sep. 30 2023      -0.62          -0.51          Beat
 Jun. 30 2023      -0.73          -0.56          Beat
 Mar. 31 2023      -0.58          -0.67          Missed